GPC KP CoP Webinar | Addressing risks of stimulant drug use among PWID (Session 2)

GPC KP CoP Webinar | Addressing risks of stimulant drug use among PWID (Session 2)

Day 1 Keynote Address - NGA Policy Academy On Stimulant And Polysubstance UseПодробнее

Day 1 Keynote Address - NGA Policy Academy On Stimulant And Polysubstance Use

1-25-2022 Webinar Spec AF Drugs in DevelopmentПодробнее

1-25-2022 Webinar Spec AF Drugs in Development

Pharmacogenomics Week 2 section 3Подробнее

Pharmacogenomics Week 2 section 3

GPC KP CoP Webinar | Addressing risks of stimulant drug use among PWID (Session 1)Подробнее

GPC KP CoP Webinar | Addressing risks of stimulant drug use among PWID (Session 1)

PCC HEALTH DEVELOPMENT OFFERS FREE SCREENING ON RALLY GROUNDПодробнее

PCC HEALTH DEVELOPMENT OFFERS FREE SCREENING ON RALLY GROUND

GPC KP CoP Webinar | Scaling Up Harm Reduction Interventions for People Who Inject & Use Drugs _1Подробнее

GPC KP CoP Webinar | Scaling Up Harm Reduction Interventions for People Who Inject & Use Drugs _1

Day 2 Keynote Address - NGA Policy Academy On Stimulant And Polysubstance UseПодробнее

Day 2 Keynote Address - NGA Policy Academy On Stimulant And Polysubstance Use

GPC KP CoP Webinar | Scaling Up Harm Reduction Interventions for People Who Inject & Use Drugs _2Подробнее

GPC KP CoP Webinar | Scaling Up Harm Reduction Interventions for People Who Inject & Use Drugs _2

Critical Treatment Issues Webinar - Session 1Подробнее

Critical Treatment Issues Webinar - Session 1

Webinar 3 ADB SD Impacts Assessment MethПодробнее

Webinar 3 ADB SD Impacts Assessment Meth

Understanding the Formation of HIV Risk Perception Among People Who Inject DrugsПодробнее

Understanding the Formation of HIV Risk Perception Among People Who Inject Drugs

Webinar: Drug Approval Process: Medications in the Global Pipeline for Covid-19Подробнее

Webinar: Drug Approval Process: Medications in the Global Pipeline for Covid-19

LHSN Webinar: Pharmacogenetics and patient safetyПодробнее

LHSN Webinar: Pharmacogenetics and patient safety

Management of drug-drug interactions and poor adherence | Kimberly Scarsi, PharmD, MS, FCCPПодробнее

Management of drug-drug interactions and poor adherence | Kimberly Scarsi, PharmD, MS, FCCP

Regulator effects with drugs and compoundsПодробнее

Regulator effects with drugs and compounds

Drug Targets, druggability, and efficacyПодробнее

Drug Targets, druggability, and efficacy

EpiCypher: Advancing Epigenomics for Drug DevelopmentПодробнее

EpiCypher: Advancing Epigenomics for Drug Development